TY - JOUR
T1 - Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa
AU - Zhang, Hong-Jie
AU - Rumschlag-Booms, Emily
AU - Guan, Yifu
AU - Wang, Dong-Ying
AU - Liu, Kang-Lun
AU - Li, Wan-Fei
AU - Nguyen, Van H.
AU - Cuong, Nguyen M.
AU - Soejarto, Djaja D.
AU - Fong, Harry H. S.
AU - Rong, Lijun
N1 - This project was supported by the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKBU 262912), the Health and Medical Research Fund (12132161) of the Food and Health Bureau, Hong Kong SAR, the Hong Kong Baptist University (HKBU) Interdisciplinary Research Matching Scheme (RC-IRMS/15-16/02), Faculty Research Grants, Hong Kong Baptist University (FRG2/11-12/134 and FRG2/14-15/047), NIH Grants 3U01TW001015-10S1 and 2U01TW001015-11A1, administered by the Fogarty International Center as part of an International Cooperative Biodiversity Groups (ICBG) program, through funds from NIH, NSF, and Foreign Agricultural Service of the USDA, and Mr. Kwok Yat Wai and Madam Kwok Chung Bo Fun Graduate School Development Fund. The authors are grateful to the Molecular Infectious Disease Core facility at Rush University Medical Center, Chicago, Illinois, USA, for conducting the anti-HIV assays against the wild-type and resistant isolates in the PBMCs.
PY - 2017/6
Y1 - 2017/6
N2 - Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M-and T-Tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.
AB - Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M-and T-Tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.
UR - http://www.scopus.com/inward/record.url?scp=85021114930&partnerID=8YFLogxK
UR - https://doi.org/10.1021/acs.jnatprod.7b00562
U2 - 10.1021/acs.jnatprod.7b00004
DO - 10.1021/acs.jnatprod.7b00004
M3 - Journal article
C2 - 28613071
AN - SCOPUS:85021114930
SN - 0163-3864
VL - 80
SP - 1798
EP - 1807
JO - Journal of Natural Products
JF - Journal of Natural Products
IS - 6
ER -